Neolife division at RPG Life Sciences was launched in July 2010 with a product mix of chemotherapy, supportive care and palliative care.
The division has been in line with its motto of launching advanced formulations with enhanced efficacy and safety. It launched NabPac, a nano particle bound paclitaxel, which has several advantages compared to its predecessor.
The division is looking forward to expand it biological and biosimilar portfolio. It launched a biosimilar, HerMab, which is used in the treatment of breast cancer.
Neolife division is in the process of launching few more advanced formulations by the way of in-licensing and co-development.